| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED OCTOBER 2020. Refer to TA659: Galcanezumab for preventing migraine for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | galcanezumab (Emgality®) | |
| Formulation | 120 mg solution for injection | |
| Reference number | 3788 | |
| Indication | Prophylaxis of migraine in adults who have at least four migraine days per month |
|
| Company | Eli Lilly & Co Ltd | |
| BNF chapter | Central nervous system | |
| Submission type | Non-submission | |
| Status | Superseded | |
| Date of issue | 15/10/2020 | |
| NICE guidance | ||
| Commercial arrangement | PAS | |